Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?

Critical Reviews in Oncology/Hematology

Volumn 95, Issue 1, 2015, Pages 88-104

  Wang Lopez, Qian ^a,b   Chalabi, Nassera ^a,c,d   Abrial, Catherine ^a,c,d   Radosevic Robin, Nina ^a,c   Durando, Xavier ^a,c,d   Mouret Reynier, Marie Ange ^a,c   Benmammar, Kheir Eddine ^a   Kullab, Sharif ^a   Bahadoor, Mohun ^a   Chollet, Philippe ^a,b   Penault Llorca, Frédérique ^a,c   Nabholtz, Jean Marc ^a,c  

^a Jean Perrin Comprehensive Cancer Centre   (France)

^b INSERM   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d UMR 766   (France)

Author keywords

Breast cancer sugroups; Neoadjuvant chemotherapy; Pathologic complete response; Surrogate marker

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NEW DRUG; TUMOR MARKER;

AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PATHOLOGIC COMPLETE RESPONSE; PREDICTIVE VALUE; REVIEW; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; BREAST; BREAST NEOPLASMS; FEMALE; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

BIOMARKERS, TUMOR; BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; NEOADJUVANT THERAPY; PROGNOSIS; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84930819401     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.02.011     Document Type: Review

References (87)

1. Perou C.M., Sørlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093.
2. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003, 100:8418-8423. 10.1073/pnas.0932692100.
3. Sørlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874. 10.1073/pnas.191367098.
4. Cheang M.C.U., Voduc D., Bajdik C., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14:1368-1376. 10.1158/1078-0432.CCR-07-1658.
5. Livasy C.A., Karaca G., Nanda R., et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006, 19:264-271. 10.1038/modpathol.3800528.
6. Esteva F.J., Hortobagyi G.N. Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?. J Natl Cancer Inst 2008, 100:521-523. 10.1093/jnci/djn098.
7. Gralow J.R., Burstein H.J., Wood W., et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 2008, 26:814-819. 10.1200/JCO.2007.15.3510.
8. Von Minckwitz G., Blohmer J.U., Costa S.D., et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2013, 31:3623-3630. 10.1200/JCO.2012.45.0940.
9. Mauri D., Pavlidis N., Ioannidis J.P.A. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005, 97:188-194. 10.1093/jnci/dji021.
10. Rastogi P., Anderson S.J., Bear H.D., et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008, 26:778-785. 10.1200/JCO.2007.15.0235.
11. Bear H.D., Anderson S., Smith R.E., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006, 24:2019-2027. 10.1200/JCO.2005.04.1665.
12. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998, 16:2672-2685.
13. Wolmark N., Wang J., Mamounas E., et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001, 96-102.
14. Kurosumi M. Significance and problems in evaluations of pathological responses to neoadjuvant therapy for breast cancer. Breast Cancer 2006, 13:254-259.
15. Le Guellec S., Perallon R., Alunni J-P., et al. Neoadjuvant treatment of breast cancer: implications for the pathologist. Ann Pathol 2011, 31:442-454. 10.1016/j.annpat.2011.10.003.
16. Penault-Llorca F., Vincent-Salomon A. Roles of the pathologist in neoadjuvant chemotherapy: evaluation of response, prognostic and predictive factors. Ann Pathol 2003, 23:555-563.
17. Kaufmann M., von Minckwitz G., Bear H.D., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007, 18:1927-1934. 10.1093/annonc/mdm201.
18. Kurosumi M., Akiyama F., Iwase T., et al. Histopathological criteria for assessment of therapeutic response in breast cancer. Breast Cancer 2001, 8:1-2.
19. Von Minckwitz G., Costa S.D., Raab G., et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol 2001, 19:3506-3515.
20. Fisher E.R., Wang J., Bryant J., et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002, 95:681-695. 10.1002/cncr.10741.
21. Ogston K.N., Miller I.D., Payne S., et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003, 12:320-327.
22. Rouzier R., Extra J-M., Klijanienko J., et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002, 20:1304-1310.
23. Feldman L.D., Hortobagyi G.N., Buzdar A.U., et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986, 46:2578-2581.
24. Honkoop A.H., Pinedo H.M., De Jong J.S., et al. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol 1997, 107:211-218.
25. Green M.C., Buzdar A.U., Smith T., et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005, 23:5983-5992. 10.1200/JCO.2005.06.232.
26. Huober J., von Minckwitz G., Denkert C., et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010, 124:133-140. 10.1007/s10549-010-1103-9.
27. Kuerer H.M., Newman L.A., Smith T.L., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999, 17:460-469.
28. Chevallier B., Roche H., Olivier J.P., et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993, 16:223-228.
29. Sataloff D.M., Mason B.A., Prestipino A.J., et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995, 180:297-306.
30. Cortazar P., Zhang L., Untch M., et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014, 384:164-172. 10.1016/S0140-6736(13)62422-8.
31. Symmans W.F., Peintinger F., Hatzis C., et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007, 25:4414-4422. 10.1200/JCO.2007.10.6823.
32. Chollet P., Abrial C., Durando X., et al. A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN). Cancer J 2008, 14:128-132. 10.1097/PPO.0b013e31816bdea2.
33. Von Minckwitz G., Untch M., Blohmer J-U., et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012, 30:1796-1804. 10.1200/JCO.2011.38.8595.
34. Kaufmann M., von Minckwitz G., Mamounas E.P., et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 2012, 19:1508-1516. 10.1245/s10434-011-2108-2.
35. Mukai H., Watanabe T., Ando M., et al. Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: standardization is needed. Breast Cancer Res Treat 2009, 113:123-128. 10.1007/s10549-007-9889-9.
36. Penault-Llorca F., Abrial C., Raoelfils I., et al. Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer. Hum Pathol 2008, 39:1221-1228. 10.1016/j.humpath.2007.11.019.
37. Bennis S., Abbass F., Akasbi Y., et al. Prevalence of molecular subtypes and prognosis of invasive breast cancer in north-east of Morocco: retrospective study. BMC Res Notes 2012, 5:436. 10.1186/1756-0500-5-436.
38. Carey L.A., Perou C.M., Livasy C.A., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502. 10.1001/jama.295.21.2492.
39. Dawood S., Hu R., Homes M.D., et al. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat 2011, 126:185-192. 10.1007/s10549-010-1113-7.
40. Haque R., Ahmed S.A., Inzhakova G., et al. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomark Prev 2012, 21:1848-1855. 10.1158/1055-9965.EPI-12-0474.
41. Bhargava R., Beriwal S., Dabbs D.J., et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer 2010, 116:1431-1439. 10.1002/cncr.24876.
42. De Ronde J.J., Hannemann J., Halfwerk H., et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 2010, 119:119-126. 10.1007/s10549-009-0499-6.
43. Glück S., de Snoo F., Peeters J., et al. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. Breast Cancer Res Treat 2013, 139:759-767. 10.1007/s10549-013-2572-4.
44. Krijgsman O., Roepman P., Zwart W., et al. A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat 2012, 133:37-47. 10.1007/s10549-011-1683-z.
45. Lips E.H., Mulder L., de Ronde J.J., et al. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat 2012, 131:827-836. 10.1007/s10549-011-1488-0.
46. Straver M.E., Glas A.M., Hannemann J., et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010, 119:551-558. 10.1007/s10549-009-0333-1.
47. Bhargava R., Striebel J., Beriwal S., et al. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol 2009, 2:444-455.
48. Von Minckwitz G., Untch M., Nüesch E., et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011, 125:145-156. 10.1007/s10549-010-1228-x.
49. Yoo C., Ahn J-H., Jung K.H., et al. Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy. J Breast Cancer 2012, 15:203-210. 10.4048/jbc.2012.15.2.203.
50. Baselga J., Bradbury I., Eidtmann H., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379:633-640. 10.1016/S0140-6736(11)61847-3.
51. Bayraktar S., Gonzalez-Angulo A.M., Lei X., et al. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer 2012, 118:2385-2393. 10.1002/cncr.26555.
52. Gianni L., Pienkowski T., Im Y-H., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:25-32. 10.1016/S1470-2045(11)70336-9.
53. Guarneri V., Frassoldati A., Bottini A., et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 2012, 30:1989-1995. 10.1200/JCO.2011.39.0823.
54. Nakamura S., Ando M., Masuda N., et al. Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancer. Clin Breast Cancer 2012, 12:49-56. 10.1016/j.clbc.2011.10.002.
55. Peintinger F., Buzdar A.U., Kuerer H.M., et al. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol 2008, 19:2020-2025. 10.1093/annonc/mdn427.
56. Pierga J-Y., Delaloge S., Espié M., et al. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat 2010, 122:429-437. 10.1007/s10549-010-0939-3.
57. Rimawi M.F., Mayer I.A., Forero A., et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol 2013, 31:1726-1731. 10.1200/JCO.2012.44.8027.
58. Untch M., Fasching P.A., Konecny G.E., et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2 - overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG Study Groups. J Clin Oncol 2011, 29:3351-3357. 10.1200/JCO.2010.31.4930.
59. Untch M., Rezai M., Loibl S., et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010, 28:2024-2031. 10.1200/JCO.2009.23.8451.
60. Madarnas Y., Trudeau M., Franek J.A., et al. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev 2008, 34:539-557. 10.1016/j.ctrv.2008.03.013.
61. Valachis A., Mauri D., Polyzos N.P., et al. Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis. Breast 2011, 20:485-490. 10.1016/j.breast.2011.06.009.
62. Schneeweiss A., Chia S., Hickish T., et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013, 24:2278-2284. 10.1093/annonc/mdt182.
63. Millikan R.C., Newman B., Tse C-K., et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008, 109:123-139. 10.1007/s10549-007-9632-6.
64. Perou C.M. Molecular stratification of triple-negative breast cancers. Oncologist 2011, 16(Suppl. 1):61-70. 10.1634/theoncologist.2011-S1-61.
65. Byrski T., Gronwald J., Huzarski T., et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010, 28:375-379. 10.1200/JCO.2008.20.7019.
66. Carey L.A., Dees E.C., Sawyer L., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13:2329-2334. 10.1158/1078-0432.CCR-06-1109.
67. Darb-Esfahani S., Loibl S., Müller B.M., et al. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res 2009, 11:R69. 10.1186/bcr2363.
68. Guarneri V., Broglio K., Kau S-W., et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006, 24:1037-1044. 10.1200/JCO.2005.02.6914.
69. Guiu S., Arnould L., Bonnetain F., et al. Pathological response and survival after neoadjuvant therapy for breast cancer: a 30-year study. Breast 2013, 22:301-308. 10.1016/j.breast.2012.07.012.
70. Hurley J., Reis I.M., Rodgers S.E., et al. The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. Breast Cancer Res Treat 2013, 138:783-794. 10.1007/s10549-013-2497-y.
71. Jeong J-H., Jung S-Y., Park I.H., et al. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Investig N Drugs 2012, 30:408-416. 10.1007/s10637-010-9555-7.
72. Kim S.I., Sohn J., Koo J.S., et al. Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Oncology 2010, 79:324-330. 10.1159/000322192.
73. Liedtke C., Mazouni C., Hess K.R., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008, 26:1275-1281. 10.1200/JCO.2007.14.4147.
74. Wu J., Li S., Jia W., et al. Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. J Cancer Res Clin Oncol 2011, 137:1505-1510. 10.1007/s00432-011-1029-6.
75. Frasci G., Comella P., Rinaldo M., et al. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol 2009, 20:1185-1192. 10.1093/annonc/mdn748.
76. Nabholtz J.M., Abrial C., Mouret-Reynier M.A., et al. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. Ann Oncol 2014, 25:1570-1577. 10.1093/annonc/mdu183.
77. Torrisi R., Balduzzi A., Ghisini R., et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol 2008, 62:667-672. 10.1007/s00280-007-0652-z.
78. Von Minckwitz G., Eidtmann H., Rezai M., et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012, 366:299-309. 10.1056/NEJMoa1111065.
79. Nabholtz J.M., Mouret-Reynier M-A., Van-Praagh I., et al. Cetuximab in combination with docetaxel (T) in patients with operable, triple-negative breast cancer (TNBC): preliminary results of a multicentre neoadjuvant pilot phase II study. J Clin Oncol 2013, 31.
80. Bear H.D., Tang G., Rastogi P., et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012, 366:310-320. 10.1056/NEJMoa1111097.
81. Sikov W.M., Berry D.A., Perou C.M., et al. Abstract S5-01: impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). Cancer Res 2013, 73. S5-01. 10.1158/0008-5472.SABCS13-S5-01.
82. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374. 10.1158/1078-0432.CCR-04-0220.
83. Kong X., Moran M.S., Zhang N., et al. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer 2011, 47:2084-2090. 10.1016/j.ejca.2011.06.014.
84. Ring A.E., Smith I.E., Ashley S., et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004, 91:2012-2017. 10.1038/sj.bjc.6602235.
85. Piccart M., Holmes A.P., de Azambuja E., et al. The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06). Cancer Res 2013, [Abstract S1-01].
86. Asaga S., Kinoshita T., Hojo T., et al. Prognostic factors for triple-negative breast cancer patients receiving preoperative systemic chemotherapy. Clin Breast Cancer 2013, 13:40-46. 10.1016/j.clbc.2012.09.013.
87. Piccart-Gebhart M.J., Holmes A.P., Baselga J., et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol 2014, 32:5s. [suppl; abstr LBA4].